Lineage Cell Therapeutics (LCTX) Long-Term Investments (2015 - 2019)

Lineage Cell Therapeutics has reported Long-Term Investments for 5 years, with the latest figure at $19.0 million in Q4 2019.

• For the quarter ending Q4 2019, Long-Term Investments fell 6.17% year-over-year to $19.0 million; the trailing twelve-month figure through Dec 2019 stood at $19.0 million (down 6.17% YoY), and the FY2019 full-year result was $19.0 million, down 6.17% from the prior year.
• Long-Term Investments for Q4 2019 stood at $19.0 million, up from $17.7 million in the prior quarter.
• The five-year high for Long-Term Investments was $110.8 million in Q3 2017, with the low at $3.5 million in Q3 2016.
• Historically, Long-Term Investments has averaged $41.3 million across 5 years, with a median of $36.5 million in 2019.
• Annual changes were most pronounced in 2017 — Long-Term Investments jumped 3082.08% — and 2018, when it slumped 70.31%.
• Lineage Cell Therapeutics' Long-Term Investments stood at $4.7 million in 2015, then soared by 2041.7% to $100.0 million in 2016, then tumbled by 31.83% to $68.2 million in 2017, then tumbled by 70.31% to $20.2 million in 2018, then retreated by 6.17% to $19.0 million in 2019.
• The last three Long-Term Investments figures came in at $19.0 million (Q4 2019), $17.7 million (Q3 2019), and $36.5 million (Q2 2019), per Business Quant data.